Literature DB >> 18851993

Rapid pathotyping of recent H5N1 highly pathogenic avian influenza viruses and of H5 viruses with low pathogenicity by RT-PCR and restriction enzyme cleavage pattern (RECP).

Sasan R Fereidouni1, Timm C Harder, Elke Starick.   

Abstract

Rapid and accurate diagnosis of avian influenza virus infections of poultry and humans comprises detection, subtyping, and, in case of subtypes H5 and H7, pathotyping of such viruses. Reliable methods for pathotyping of H5 avian influenza viruses (AIV) are based on determination of the intravenous pathogenicity index (IVPI) in specific pathogen free (SPF) chickens and on characterization of the hemagglutinin (HA) gene cleavage site by sequencing. The number of basic amino acids (arginine and lysine) at the cleavage site is an important indicator of pathogenicity. In this paper, a new rapid method for pathotyping of H5 subtype avian influenza viruses is described which is based on RT-PCR and restriction enzyme cleavage pattern (RECP) assay using the MboII restriction enzyme. Validation of the method using 28 H5 subtype reference isolates from different animal species revealed good performance characteristics regarding sensitivity and specificity, especially when targeting recent highly pathogenic AIV (HPAIV) of subtype H5N1 and Asian origin. In addition, RECP results were validated by testing 47 field samples from different sources and by sequencing of their RT-PCR products. This approach for H5 AIV pathotyping proved to be fast, reliable, and comparatively sensitive and is suitable especially for laboratories lacking sequencing or in vivo pathotyping facilities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18851993     DOI: 10.1016/j.jviromet.2008.09.011

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  5 in total

1.  Alterations in hemagglutinin receptor-binding specificity accompany the emergence of highly pathogenic avian influenza viruses.

Authors:  Alla Heider; Larisa Mochalova; Timm Harder; Alexander Tuzikov; Nicolai Bovin; Thorsten Wolff; Mikhail Matrosovich; Brunhilde Schweiger
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

2.  Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.

Authors:  Donald F Smee; Brett L Hurst; Min-Hui Wong; Kevin W Bailey; E Bart Tarbet; John D Morrey; Yousuke Furuta
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

3.  Avian influenza virus monitoring in wintering waterbirds in Iran, 2003-2007.

Authors:  Sasan R Fereidouni; Ortrud Werner; Elke Starick; Martin Beer; Timm C Harder; Mehdi Aghakhan; Hossein Modirrousta; Hamid Amini; Majid Kharrazian Moghaddam; Mohammad H Bozorghmehrifard; Mohammad A Akhavizadegan; Nicolas Gaidet; Scott H Newman; Saliha Hammoumi; Giovanni Cattoli; Anja Globig; Bernd Hoffmann; Mohammad E Sehati; Siamak Masoodi; Tim Dodman; Ward Hagemeijer; Shirin Mousakhani; Thomas C Mettenleiter
Journal:  Virol J       Date:  2010-02-19       Impact factor: 4.099

4.  Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.

Authors:  Donald F Smee; Brett L Hurst; Min-Hui Wong; Kevin W Bailey; John D Morrey
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

5.  European surveillance network for influenza in pigs: surveillance programs, diagnostic tools and Swine influenza virus subtypes identified in 14 European countries from 2010 to 2013.

Authors:  Gaëlle Simon; Lars E Larsen; Ralf Dürrwald; Emanuela Foni; Timm Harder; Kristien Van Reeth; Iwona Markowska-Daniel; Scott M Reid; Adam Dan; Jaime Maldonado; Anita Huovilainen; Charalambos Billinis; Irit Davidson; Montserrat Agüero; Thaïs Vila; Séverine Hervé; Solvej Østergaard Breum; Chiara Chiapponi; Kinga Urbaniak; Constantinos S Kyriakis; Ian H Brown; Willie Loeffen
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.